by Raymond Tel | Mar 28, 2024 | News
Sulfateq is happy to announce that a new scientific manuscript detailing the safety of SUL-138 is published in the leading journal Toxicology Reports. This manuscript details the safety, tolerability and toxicokinetic data of SUL-138, an obligatory step in drug...
by Raymond Tel | Feb 24, 2024 | News
This week, the first dosings of SUL-238 in healthy volunteers in a Phase I study marks a major milestone in the clinical development of this hibernation-derived, first-in-class drug. The phase I study investigates the safety, tolerability and pharmacokinetics after...
by Raymond Tel | Apr 7, 2023 | News
Great news! A new scientific paper has been published about the potential of a new medicine, SUL-138, to help treat sepsis. Sepsis is a serious health problem, but right now doctors can only use antibiotics and supportive care to help patients. SUL-138 targets the...
by Raymond Tel | Dec 14, 2022 | News
Alzheimer’s Disease (AD) is a complex and progressive neurodegenerative disease which is characterized by memory loss and cognitive impairment. It is one of the most prevalent neurodegenerative diseases and it is estimated that the number of patients will increase...